CrownBio’s library of focussed FactSheets on
key Oncology and CVMD preclinical topics


Let CrownBio Be A Resource For You

The CrownBio library of focused FactSheets brings you highly specific information on a single topic, service, or subset of models to meet your Oncology and Cardiovascular and Metabolic Disease (CVMD) research needs.

The FactSheet collection continues to grow and is regularly updated with our latest service and model updates. Bookmark this page and come back and see us soon. Don’t see what you need? Contact us today with your request.

Cardiovascular and Metabolic Disease (CVMD)

CrownBio provides a range of FactSheets across our key disease areas, including:

Cardiovascular Disease  

  • Rodent models of cardiovascular disease technologies and resources including continuous telemetry blood pressure monitoring
  • The ZDSD polygenic rat model with functional leptin pathway, a highly translatable model which develops hypertension



  • The FATZO-NAFLD/NASH model, which develops NAFLD/NASH in an inherently dysmetabolic, obese, and diabetic mouse model, and more closely resembles human disease progression in the context of dysmetabolism


Renal Disease    




CrownBio provides a comprehensive In Vivo Immunotherapy Translational Technology Platform, and our FactSheets bring you detailed information across a range of our immuno-oncology services:

CAR-T Cell Therapy Models

Humanized Models

Murine Efficacy/PD Models

  • Syngeneic models, showcasing our ever expanding syngeneic collection, FACS analysis, and checkpoint inhibitor benchmarking
  • MuScreen™ CrownBio’s large-scale, staggered screening platform to fast-track the in vivo screening of immunotherapy compounds
  • MuPrime™ - homografts of spontaneous murine tumors (from GEMM/carcinogen-induced models), studied in mice with complete immunocompetency
  • MuPrime mBR6004 which takes a closer look at our most highly studied MuPrime model including gene expression, immunohistochemistry, treatment data, and immune cell tumor infiltration analysis

Fusion Models 

Fusion oncogenic events are important targets for oncology research, potentially providing ‘druggable’ targets for subsets of cancer patients. We currently provide FactSheets on:

  • RET fusion in CRC PDX models, including model response to RET inhibitor treatment, and the development of acquired resistance models
  • Our FGFR3 fusion in vivo xenograft platform covering both patient and cell line derived xenografts over a range of cancer types, to advance preclinical FGFR inhibitor development

PDX Models 

  • Our PDX collection key features are summarized in our HuPrime® FactSheet
  • Discover our validated stable HuKemia® models, the only commercial blood cancer PDX models to truly represent the human condition
  • Use the world's most comprehensive GIST PDX collection to evaluate the next generation of anticancer agents to overcome imatinib resistance
  • Read how to accelerate NHL DLBCL targeted agent and combination therapy drug discovery programs with PDX models fully characterized for DLBCL related genes

Optical Imaging Platform

  • Utilize our clinically relevant optical imaging models to enable in-life visualization of tumor growth and disease progression, from orthotopic sites to metastatic lesions.


  • Use our unique online database MuBase® to quickly and easily identify the most suitable murine efficacy/PD or humanized drug target models for your preclinical immuno-oncology studies.

In Vitro/Ex Vivo Assays